Shire (NASDAQ:SHPG) has been given a $222.00 price objective by equities research analysts at Cantor Fitzgerald in a report released on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 41.96% from the company’s previous close. Cantor Fitzgerald also issued estimates for Shire’s FY2018 earnings at $15.18 EPS.
Several other equities analysts have also issued reports on the company. Zacks Investment Research upgraded Shire from a “sell” rating to a “hold” rating in a research note on Friday, October 27th. ValuEngine lowered Shire from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Royal Bank of Canada reiterated a “buy” rating on shares of Shire in a research note on Thursday, November 16th. Cowen set a $225.00 target price on Shire and gave the company a “buy” rating in a research note on Sunday, October 29th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 target price on shares of Shire in a research note on Sunday, October 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $212.18.
Shire (NASDAQ SHPG) opened at $156.38 on Wednesday. Shire has a 52 week low of $137.17 and a 52 week high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $47,020.00, a PE ratio of 29.45, a price-to-earnings-growth ratio of 0.90 and a beta of 1.59.
A number of hedge funds and other institutional investors have recently modified their holdings of SHPG. Canal Insurance CO purchased a new position in Shire during the second quarter valued at approximately $102,000. Whittier Trust Co. raised its position in Shire by 19.1% during the first quarter. Whittier Trust Co. now owns 573 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 92 shares in the last quarter. Pinnacle Bank purchased a new position in Shire during the first quarter valued at approximately $101,000. FTB Advisors Inc. raised its position in Shire by 3.1% during the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 18 shares in the last quarter. Finally, Duncker Streett & Co. Inc. purchased a new position in Shire during the second quarter valued at approximately $111,000. 20.19% of the stock is owned by institutional investors and hedge funds.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
